Evidence map›Paper›PMID 34699015›Full record

ArticleGlycoconjugate journal2022

Structural characteristics of Heparan sulfate required for the binding with the virus processing Enzyme Furin.

Jiaxin Zeng, Yuan Meng, Shi-Yi Chen, Gaofeng Zhao, Lianchun Wang, En-Xin Zhang, Hong Qiu

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Glycoconjugate journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Is heparan sulfate a target for inhibition of RNA virus infection?American journal of physiology. Cell physiology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Jiaxin ZengThe First Affiliated Hospital of Guangzhou University of Chinese Medicine, No. 16 Jichang Road, Guangdong Province, 510405, Guangzhou, China.
Yuan MengCarbohydrate-Based Drug Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 200031, China.
Shi-Yi ChenCarbohydrate-Based Drug Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 200031, China.
Gaofeng ZhaoCarbohydrate-Based Drug Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 200031, China.
Lianchun WangDepartment of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida Health, Tampa, FL, USA.
En-Xin ZhangThe First Affiliated Hospital of Guangzhou University of Chinese Medicine, No. 16 Jichang Road, Guangdong Province, 510405, Guangzhou, China. ergep53@126.com.
Hong QiuCarbohydrate-Based Drug Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 200031, China. hongqiu@simm.ac.cn.ORCID 0000-0002-4088-7828
Chinese Academy of Sciences · CNNanjing University of Chinese Medicine · CNFirst Affiliated Hospital of Guangzhou University of Chinese Medicine · CNUniversity of South Florida · US

Funding

Heparan Sulfate 3-O-Sulfation in Transcellular Propagation of Tauopathy in Alzheimer's DiseaseRF1AG069039 · NIA · RENSSELAER POLYTECHNIC INSTITUTE · PI LINHARDT, ROBERT J, LIU, JIAN · 2020 to 2020
$2.6M
Heparan Sulfate in Prostate CancerU01CA225784 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI CAI, HOUJIAN, WANG, LIANCHUN · 2018 to 2023
$2.6M
Heparan sulfate proteoglycan in the brain vascular clearance of amyloid-β and Alzheimer's diseaseRF1AG074289 · NIA · UNIVERSITY OF SOUTH FLORIDA · PI WANG, LIANCHUN · 2021 to 2021
$1.8M
Predoctoral Training Program for Alzheimer’s Disease at the Interface of Data Science, Engineering and BiologyT32AG078123 · NIA · RENSSELAER POLYTECHNIC INSTITUTE · PI Chunyu Wang · 2023 to 2026
$974k
Heparan sulfate proteoglycan in Alzheimer's diseaseR56AG062344 · NIA · UNIVERSITY OF SOUTH FLORIDA · PI WANG, LIANCHUN · 2018 to 2018
$785k
NCI NIH HHS U01 CA225784NIA NIH HHS R56 AG062344NIA NIH HHS RF1 AG069039NIA NIH HHS RF1 AG074289NIA NIH HHS T32 AG078123
6 · The paper itself

Abstract

Furin is one of the nine-member proprotein convertase family. Furin cleaves proteins with polybasic residues, which includes many viral glycoproteins such as SARS-Cov-2 spike protein. The cleavage is required for the activation of the proteins. Currently, the mechanisms that regulate Furin activity remain largely unknown. Here we demonstrated that Furin is a novel heparin/heparan sulfate binding protein by the use of biochemical and genetic assays. The K

Indexed as

FurinHeparan SulfateHumansSARS-CoV-2Spike Glycoprotein, CoronavirusFurinHeparan SulfateSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Carbohydrate-protein interactionFurinHeparan sulfateHeparinVirus infection

Identifiers

PMID34699015
PMCPMC8546381
OpenAlexW3208299284

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.